Patents by Inventor Ward C. Tucker

Ward C. Tucker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240117408
    Abstract: Cells are described that are useful in rapid, sensitive, and accurate cell-based assays for enzyme activity, particularly for enzyme activities associated with botulinum toxins. Such cell expresses a construct that includes an anchor region, a cleavage site, and a reporting region having two or more identical reporter peptides. Enzymatic activity at the cleavage site releases the reporter region into the cytosol of the cell, where multiple degradation events occur. The observed change in the signal is proportional to the enzymatic activity.
    Type: Application
    Filed: May 18, 2023
    Publication date: April 11, 2024
    Inventor: Ward C Tucker
  • Publication number: 20240002443
    Abstract: Recombinant nucleic acids encoding reporting constructs for characterizing botulinum neurotoxin protease activity and cells that incorporate such recombinant nucleic acids and that are suitable for use in cell-based assays for the neurotoxin are provided. The encoded reporting constructs are a pair of recombinant hybrid proteins that act in concert. The reporting constructs are a pair of recombinant hybrid proteins that act in concert, and that include a botulinum neurotoxin protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage.
    Type: Application
    Filed: April 21, 2023
    Publication date: January 4, 2024
    Inventors: Ward C Tucker, Francis Mark Dunning
  • Patent number: 11685945
    Abstract: Compositions and methods are disclosed that provide a rapid, sensitive, and accurate cell-based assay for enzyme activity, particularly for enzyme activities associated with botulinum toxins. A cell is provided that expresses a construct that includes an anchor region, a cleavage site, and a reporting region having two or more identical reporter peptides. Enzymatic activity at the cleavage site releases the reporter region into the cytosol, where multiple degradation events occur. The observed change in the signal is proportional to the enzymatic activity.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: June 27, 2023
    Assignee: BioMadison, Inc.
    Inventor: Ward C Tucker
  • Patent number: 11661442
    Abstract: Vesicles that incorporate reporting constructs for characterizing Botulinum neurotoxin protease activity and suitable for use in an assay are provided. The reporting constructs are a pair of recombinant hybrid proteins that act in concert. The reporting constructs are a pair of recombinant hybrid proteins that act in concert, and that include a Botulinum neurotoxin protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: May 30, 2023
    Assignee: BioMadison, Inc.
    Inventors: Ward C Tucker, Francis Mark Dunning
  • Publication number: 20230143149
    Abstract: Systems are described in which a primary detergent or surfactant in an aqueous solution is removed by the addition of a secondary detergent or surfactant in concentrations that exceed the critical micellar concentration (CMC) of the secondary detergent or surfactant using a size separation device. These systems are particularly applicable to protein-containing solutions. Typical primary detergents/surfactants include polysorbate 20, polysorbate 80, and Triton X-100. Suitable secondary detergents or surfactants can be ionic, nonionic, or zwitterionic. Typical secondary detergents/surfactants include, but are not limited to, galactoside detergents (e.g. octyl-?-galactoside), glucamide detergents (e.g. MEGA 8, MEGA 9, MEGA 10), cholamide detergents (e.g. CHAPS, CHAPSO, BIGCHAPS), and sulfobetaine detergents (such as sulfobetaine 3-10).
    Type: Application
    Filed: January 9, 2023
    Publication date: May 11, 2023
    Inventors: Francis Mark Dunning, Ward C. Tucker
  • Patent number: 11578099
    Abstract: Compositions and methods are described in which a primary detergent or surfactant in an aqueous solution is removed by the addition of a secondary detergent or surfactant in concentrations that exceed the critical micellar concentration (CMC) of the secondary detergent or surfactant. These compositions and methods are particularly applicable to protein-containing solutions. Typical primary detergents/surfactants include polysorbate 20, polysorbate 80, and Triton X-100. Suitable secondary detergents or surfactants can be ionic, nonionic, or zwitterionic. Typical secondary detergents/surfactants include, but are not limited to, galactoside detergents (e.g. octyl-?-galactoside), glucamide detergents (e.g. MEGA 8, MEGA 9, MEGA 10), cholamide detergents (e.g. CHAPS, CHAPSO, BIGCHAPS), and sulfobetaine detergents (such as sulfobetaine 3-10).
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: February 14, 2023
    Assignee: BioMadison, Inc.
    Inventors: Francis Mark Dunning, Ward C. Tucker
  • Publication number: 20220373547
    Abstract: Compositions for determining the efficacy and/or potency of a vaccine preparation are described herein. Splenocytes from immunized animals are isolated and can be frozen. Upon thawing such cells are activated by exposure to a series of dilutions of a vaccine preparation being tested and a series of dilutions of a reference vaccine with known characteristics. Cells secreting immunogen-specific antibody and cells secreting nonspecific antibody are enumerated, as is the amount of immunogen-specific and nonspecific antibody produced. Comparison between the results from the vaccine preparations provides a measure of relative vaccine efficacy and/or potency.
    Type: Application
    Filed: August 2, 2022
    Publication date: November 24, 2022
    Inventor: Ward C. Tucker
  • Patent number: 11435351
    Abstract: Compositions and methods for determining the efficacy and/or potency of a vaccine preparation are described herein. Splenocytes from immunized animals are isolated and frozen. Upon thawing aliquots these cells are activated by exposure to a series of dilutions of q vaccine preparation being tested and a series of dilutions of a reference vaccine with known characteristics. Cells secreting immunogen-specific antibody and cells secreting nonspecific antibody are enumerated, as is the amount of immunogen-specific and nonspecific antibody produced. Comparison between the results from the vaccine preparations provides a measure of relative vaccine efficacy and/or potency.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: September 6, 2022
    Assignee: BioMadison, Inc.
    Inventor: Ward C Tucker
  • Publication number: 20220260555
    Abstract: Compositions and methods for characterization binding proteins are described that include use of a reporting construct that incorporates a bait region that interacts with the binding protein and a reporter that is susceptible to degradation in the reporter's local environment. Complex formation between the bait region and the binding protein provides protection of the susceptible reporter from degradation. Such a reporting construct can be utilized to identify cells expressing a binding protein when the susceptible reporter is susceptible to degradation in cytosol.
    Type: Application
    Filed: April 13, 2022
    Publication date: August 18, 2022
    Inventors: Dhammika ATAPATTU, Ward C. TUCKER
  • Publication number: 20220244256
    Abstract: Cell based assays for botulinum neurotoxin are provided. Specific neurotoxin uptake or proteolytic activity directed to reporting constructs sensitive to botulinum neurotoxin in cells capable of being intoxicated by botulinum neurotoxin is enhanced by increasing expression of SV2 or heat shock proteins in such cells, respectively.
    Type: Application
    Filed: April 13, 2022
    Publication date: August 4, 2022
    Inventors: Ward C. Tucker, Timothy M. Piazza
  • Publication number: 20220196634
    Abstract: Compositions and methods for improved cell-based methods of characterizing botulinum neurotoxins are provided. Cells utilized in these methods include a reporting construct that is cleaved following uptake and processing of botulinum neurotoxin by the cell, resulting in proteolysis of the portion of the reporting construct that is released following cleavage. The released portion includes a fluorophore and amino acid substitutions or sequences that enhance the rate of proteolysis. A pair of reporting constructs can be utilized in which one member of the pair is modified to resist cleavage by the botulinum neurotoxin while co-localizing with the remaining member of the pair.
    Type: Application
    Filed: January 25, 2022
    Publication date: June 23, 2022
    Inventors: Timothy Piazza, Francis Mark Dunning, Ward C Tucker
  • Patent number: 11333664
    Abstract: Methods for increasing specific uptake of a Botulinum neurotoxin are provided. Specific neurotoxin uptake by cells capable of being intoxicated by Botulinum neurotoxin is enhanced by increasing temperature from about 37° C. to up to about 41° C., as indicated by a decrease in the EC50 found for cells so treated. The effect requires the presence of both heavy and light chains of the Botulinum neurotoxin, and is serotype selective.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: May 17, 2022
    Assignee: BioMadison, Inc.
    Inventors: Ward C. Tucker, Timothy M. Piazza
  • Patent number: 11325954
    Abstract: Compositions for characterization of botulinum toxin (BoNT) are described that include a genetically modified cell that is transfected with an artificial construct comprising a nucleic acid sequence that encodes for a hybrid protein having (a) a reporter-containing portion chemically coupled to (b) a cleavage site and (c) a control fluorophore. The cleavage site interacts with a BoNT in a manner that cleaves the reporter-containing portion from remainder of the construct. The cleaved portion is destroyed or otherwise degraded by the local environment, and presence of BoNT is evidenced by reduction in signal from the reporter. The cleavage sequence is all or part of a SNARE protein, the cleavable reporter-containing portion is preferably Yellow Fluorescent Protein (YFP), Citrine, Venus, or a YPet protein and the control fluorophore is preferably CFP, mStrawberry, or a mCherry protein.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: May 10, 2022
    Assignee: BioMadison, Inc.
    Inventors: Dhammika Atapattu, Ward C. Tucker
  • Patent number: 11320420
    Abstract: Compositions and methods are provided that reduce the time required for detection of botulinum neurotoxins in cell-based assays. In one aspect an isoquinolynyl compound can be used for this purpose. In such cell-based assays the cell can include an enzyme that facilitates degradation of the reporter significantly faster after the cleavage than before the cleavage, and presence of the Botulinum toxin correlates with reduction of the signal from a baseline signal. The cell can advantageously express both the construct that includes the reporter, and an enzyme that facilitates the degradation.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: May 3, 2022
    Assignee: BioMadison, Inc.
    Inventors: Tim Piazza, Ward C Tucker
  • Publication number: 20210269485
    Abstract: Vesicles that incorporate reporting constructs for characterizing Botulinum neurotoxin protease activity and suitable for use in an assay are provided. The reporting constructs are a pair of recombinant hybrid proteins that act in concert. The reporting constructs are a pair of recombinant hybrid proteins that act in concert, and that include a Botulinum neurotoxin protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage.
    Type: Application
    Filed: March 22, 2021
    Publication date: September 2, 2021
    Inventors: Ward C Tucker, Francis Mark Dunning
  • Patent number: 10975125
    Abstract: Reporting constructs for characterizing Botulinum neurotoxin protease activity and suitable for use in a cell-based assay are provided. The reporting construct can be a single recombinant hybrid protein or a pair of recombinant hybrid proteins that act in concert. The recombinant hybrid protein(s) include a fluorophore and an N-terminal non-peptide membrane anchoring portion. The recombinant hybrid protein or at least one of a pair of recombinant hybrid proteins that act in concert include a Botulinum neurotoxin protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: April 13, 2021
    Assignee: BioMadison, Inc.
    Inventors: Ward C Tucker, Francis Mark Dunning
  • Publication number: 20210032675
    Abstract: Compositions and methods are disclosed that provide a rapid, sensitive, and accurate cell-based assay for enzyme activity, particularly for enzyme activities associated with botulinum toxins. A cell is provided that expresses a construct that includes an anchor region, a cleavage site, and a reporting region having two or more identical reporter peptides. Enzymatic activity at the cleavage site releases the reporter region into the cytosol, where multiple degradation events occur. The observed change in the signal is proportional to the enzymatic activity.
    Type: Application
    Filed: February 6, 2020
    Publication date: February 4, 2021
    Inventor: Ward C Tucker
  • Patent number: 10908146
    Abstract: Compositions and methods are provided that improve detection of botulinum neurotoxins in cell-based assays. In one aspect an isoquinolynyl compound can be used to enhance the sensitivity of both Förster resonance energy transfer (FRET) and non-FRET cell-based assays. Osmolarity of the cell culture media can be adjusted to optimize the effect of the compound. In that subject matter an environment cell can include an enzyme that facilitates degradation of the reporter significantly faster after the cleavage than before the cleavage, and presence of the Botulinum toxin correlates with reduction of the signal from a baseline signal. Where the environment is a cell, the cell can advantageously express both the construct that includes the reporter, and an enzyme that facilitates the degradation.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: February 2, 2021
    Assignee: BioMadison, Inc.
    Inventors: TIm Piazza, Ward C Tucker
  • Publication number: 20210011002
    Abstract: Compositions and methods are provided that reduce the time required for detection of botulinum neurotoxins in cell-based assays. In one aspect an isoquinolynyl compound can be used for this purpose. In such cell-based assays the cell can include an enzyme that facilitates degradation of the reporter significantly faster after the cleavage than before the cleavage, and presence of the Botulinum toxin correlates with reduction of the signal from a baseline signal. The cell can advantageously express both the construct that includes the reporter, and an enzyme that facilitates the degradation.
    Type: Application
    Filed: June 15, 2020
    Publication date: January 14, 2021
    Inventors: Tim Piazza, Ward C. Tucker
  • Publication number: 20200363412
    Abstract: Methods for increasing specific uptake of a Botulinum neurotoxin are provided. Specific neurotoxin uptake by cells capable of being intoxicated by Botulinum neurotoxin is enhanced by increasing temperature from about 37° C. to up to about 41° C., as indicated by a decrease in the EC50 found for cells so treated. The effect requires the presence of both heavy and light chains of the Botulinum neurotoxin, and is serotype selective.
    Type: Application
    Filed: August 5, 2020
    Publication date: November 19, 2020
    Inventors: Ward C. Tucker, Timothy M. Piazza